Oxford Nanopore Technologies

Oxford Nanopore Technologies, a UK-based pharmaceutical preparation manufacturer, reported its 2024 Scope 3 emissions as approximately 51,215 tonnes CO2e. This follows Scope 3 emissions of around 51,814 tonnes CO2e in 2023. In 2022, their total greenhouse gas emissions were approximately 56,668 tonnes CO2e, comprising 592 tonnes CO2e from Scope 1, 959 tonnes CO2e from Scope 2, and 54,495 tonnes CO2e from Scope 3. Earlier, in 2021, Scope 1 and 2 emissions totalled about 1,570 tonnes CO2e (393 tonnes CO2e for Scope 1 and 1,178 tonnes CO2e for Scope 2), and in 2020, Scope 1 and 2 emissions were roughly 1,450.9 tonnes CO2e (359.2 tonnes CO2e for Scope 1 and 1,091.7 tonnes CO2e for Scope 2).

Oxford Nanopore Technologies is committed to ambitious climate targets. The company has set a long-term goal to achieve net-zero greenhouse gas emissions across its entire value chain by 2045, with a target of at least a 90% reduction in Scope 1, 2, and 3 emissions by this date, using a 2023 base year.

For near-term reductions, Oxford Nanopore Technologies aims to decrease absolute Scope 1 and 2 GHG emissions by 42% by 2030, also from a 2023 base year. Additionally, they are committed to reducing Scope 3 GHG emissions by 52% per GBP value added within the same 2023-2030 timeframe. These targets are validated by the Science Based Targets initiative (SBTi), classifying their near-term Scope 1 and 2 targets as consistent with a 1.5°C warming scenario.